AVEG 023

A Phase I Trial to Evaluate the Safety and Immunogenicity of the UBI HIV-1 MN PND Peptide Immunogen, Given by IM Injection, in Vombination with the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide, Given Orally, In HIV-1 Uninfected Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) May 18, 1995
UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent Env V3 loop gp120 B MN
UBI HIV-1 Peptide Immunogen, Multivalent Protein
USA 36